Pavlakis, N., Ananda, S., Chan, H., Harris, M., Joubert, W. L., Kim, J. W., Lee, C., Lee, W., Lipton, L., Nagrial, A., Oh, D. Y., Park, J. O., Cock, T., Kinkel, S., Kruger, N., Burns, C., Lickliter, J. (2026). Narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel as first-line treatment for patients with metastatic pancreatic cancer (ACCENT trial): Phase 2a results.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.2_suppl.735